DS STAGE I MULTIPLE MYELOMA
Clinical trials for DS STAGE I MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new DS STAGE I MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for DS STAGE I MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a pill after transplant keep myeloma at bay?
Disease control OngoingThis phase 3 trial studies whether taking lenalidomide (Revlimid) after an autologous stem cell transplant can delay the return of multiple myeloma compared to a placebo. About 460 patients with active myeloma who had a stem cell transplant are involved. The main goal is to see h…
Matched conditions: DS STAGE I MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Myeloma showdown: does adding a third drug boost survival?
Disease control OngoingThis phase 3 trial compares two treatment combinations for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. One group gets lenalidomide plus low-dose dexamethasone, while the other gets those two drugs plus bortezomib. The goal …
Matched conditions: DS STAGE I MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New combo shows promise in myeloma battle
Disease control OngoingThis study tested two different doses of dexamethasone combined with lenalidomide in 452 people newly diagnosed with multiple myeloma. The goal was to see which dose worked better at shrinking tumors. If the first treatment didn't work, patients could switch to a thalidomide-base…
Matched conditions: DS STAGE I MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC